ECO 2026
12 - 15 May 2026
Once-Weekly Subcutaneous CagriSema Does Not Affect the Exposure of Atorvastatin or Warfarin in People Living With Overweight or Obesity
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.